News

Zepbound beats Wegovy rival in 1st head-to-head weight loss study
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.
BioSpace40m
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
Zepbound outperforms Wegovy in head-to-head weight loss trial
Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.
Today's Dietitian52m
Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle
News Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle. Diabetes and obesity have become pressing health issues worldwide. Glucagon-lik ...
E! Online1h
Kyle Richards’ Daughter Sophia Umansky Slams Criticism Over Weight Loss Medication
Sophia Umansky—the daughter of Kyle Richards and Mauricio Umansky—doubled down on her decision to take Mounjaro, despite ...
Endpoints News2h
Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy
New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...
Boston scientists join $81m quest to extend human healthspan
About 600 college leaders recently signed a letter opposing the Trump administration's interference in higher education. The ...
Billionaire Chase Coleman Has 68% of His $24.5 Billion Portfolio Invested in 10 Stocks. Here's the Best of the Bunch.
Billionaire Chase Coleman Has 68% of His $24.5 Billion Portfolio Invested in 10 Stocks. Here's the Best of the Bunch.
Mass. residents who take GLP-1 drugs for obesity tend to be white and affluent. But who needs them most?
The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...